Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: omecamtiv mecarbil, a cardiac myosin activator for the potential treatment of heart failure, CK-136, a cardiac troponin activator, reldesemtiv, a skeletal muscle troponin activator, and CK-3773274, a cardiac myosin inhibitor which is designed to reduce the hypercontractility that is associated with hypertrophic cardiomyopathy. The CYTK stock yearly return is shown above.
The yearly return on the CYTK stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CYTK annual return calculation with any dividends reinvested as applicable (on ex-dates).
|